September 2021

We are very proud to announce our strategic alliance with HELM AG on a worldwide basis in the co-development, registration, manufacture and commercialization of oral solution products, either generic versions of currently registered product or innovative ideas. This represents a huge milestone for Labomed that continues to create partnerships around the world, which will result …

Strategic alliance with HELM AG on a worldwide basis Read More »

Labomed S.A. is delighted to announce the completed and successful vaccination of its personnel.At Labomed, we have taken all the necessary actions that support Covid – 19 vaccine adoption.During this unprecedented healthcare crisis, our team has been encouraged and motivated to get vaccinated.Labomed adheres to all the appropriate state protocols against the Covid- 19 infection …

Labomed S.A. is delighted to announce the completed and successful vaccination of its personnel. Read More »

Labomed S.A is proud to announce the successful Pivotal BE outcome of Lisdexamfetamine Oral Solution 10mg/ml that has been co-sponsored & developed with Adalvo & Pharma-Data at our premises. We are moving ahead with the regulatory EU submission & US tech. transfer, whereby DCP slots have already been granted.This added value version of Lisdexamfetamine comes in the …

Labomed S.A is proud to announce the successful Pivotal BE outcome of Lisdexamfetamine Oral Solution Read More »